The Role of Vitamin D in Multiple Sclerosis: Biology and Biochemistry, Epidemiology and Potential Roles in Treatment.
Med Chem. 2018 Feb 6;14(2):129-143. doi: 10.2174/1573406413666170921143600.
Simpson S Jr1, der Mei IV1, Taylor B1.
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
along with graph of MS increase
- Multiple Sclerosis 40 percent more likely if mother had low vitamin D – meta-analysis Jan 2020
- Risk of Multiple Sclerosis varies with the Vitamin D Receptor – meta-analysis Dec 2019
- MS not treated by Vitamin D (a few old studies using small doses) – Meta-analysis July 2018
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Fewer Multiple Sclerosis lesions when supplemented with Vitamin D – meta-analysis May 2017
- Multiple Sclerosis and small doses of Vitamin D – meta-review March 2016
- Multiple sclerosis patients have 15 ng lower levels of vitamin D – meta-analysis June 2014
- Multiple Sclerosis and the Vitamin D Receptor – meta-analysis July 2014
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- No association between Multiple Sclerosis relapses and being treated with vitamin D–meta-analysis May 2013
- Multiple Sclerosis 23 percent more likely if born in April vs. Oct – meta-analysis Nov 2012
- 53 Multiple Sclerosis patients somewhat helped by 10,000 IU of vitamin D (vs, 30,000 virtually cured by 10X as much) – Jan 2020
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis Relapsing-Remitting rate reduced 30 percent by addition of 14,000 IU vitamin D daily – RCT Nov 2016
- Multiple sclerosis helped some by 10,000 IU of vitamin D daily avg. for 3 months – RCT Sept 2016
- Vitamin D has already cleared 100 percent of lesions from over 1,000 MS patients in Brazil
- Dr. Coimbra explains his treatment with high dose vitamin D for multiple sclerosis – Feb 2015
- No multiple sclerosis relapses during pregnancy if 50,000 IU of Vitamin D weekly – RCT April 2015
- 1000 IU per kg Vitamin D for autoimmune diseases – Coimbra Aug 2013
- Optic neuritis progession into Multiple Sclerosis reduced 68 percent by 50,000 IU of vitamin D weekly
- Video by Dr. Coimbra – 95 percent of auto-immune cured with vitamin D in high doses - April 2014
- Autoimmune disorder patients in Brazil helped by vitamin D – video and Facebook – Nov 2012
- Risk of going from pre-MS to MS reduced 68 percent with 7100 IU vitamin D – RCT Dec 2012
- MS helped by average daily 2800 IU vitamin D – RCT Aug 2012
- CureTogether Vitamin D symptoms, treatments, and causes
- Yet again - more than 10000 IU of vitamin D treats MS – July 2011
- Overview MS and vitamin D
- MS prevention by UV is 2X better than prevention by vitamin D levels – Jan 2012
- Multiple Sclerosis, Alzheimer’s and Parkinson’s need more than 30 ng of Vitamin D – review Nov 2017
- Vitamin D and multiple sclerosis—from epidemiology to prevention – June 2015
- Multiple Sclerosis prevention by Vitamin D: 10 year, 30 million dollar trial - Sept 2013
- 5,000 IU is one leg of the trial
- Prevention with vitamin D in Multiple Sclerosis is logical – editorial April 2013
- Vitamin D prevents multiple sclerosis through multiple mechanisms – Jan 2013 Excellent, 26 pages, many good charts
Multiple sclerosis (MS) is a progressive, demyelinating condition of the central nervous system, manifesting in loss or alterations in function of sensory, motor and cognitive function. Of the various environmental and behavioural risk factors identified as playing a role in MS onset and progression, perhaps none has been as consistent as vitamin D.
In this review, we will endeavour to present a general background on the role of vitamin D in human health and particularly in MS, as well as the substantial epidemiological evidence in support of vitamin D's role in MS.
Initially identified via the oft-noted latitudinal gradient in MS prevalence and incidence, vitamin D has since been demonstrated to have a
- strong and consistent inverse association with MS risk and clinical course.
Cases have much lower levels of the diagnostic metabolite of vitamin D, 25- hydroxyvitamin D (25(OH)D) compared to healthy controls,
while those with more active disease have lower levels of 25(OH)D than other cases with less active disease.
These case-control and crosssectional study results led the way to cohort studies which indicated
- significant inverse associations between serum 25(OH)D and clinical activity in MS.
The combined weight of indirect and direct observational evidence have been the
- impetus for completed and ongoing randomised trials of vitamin D supplementation, alone or in addition to standard immunomodulatory medications, as an intervention in MS onset and clinical course.
Moreover, in addition to being a distinct factor in MS aetiology, vitamin D has been demonstrated to interact with a variety of other risk factors, from genetic predictors like HLA-DR1 genotype to behavioural factors like smoking.
There is an abundance of epidemiological evidence, both direct and indirect, as well as significant biological plausibility substantiating a role for vitamin D in the onset and progression of multiple sclerosis.
PMID: 28933265 DOI: 10.2174/1573406413666170921143600